Chih-Hung Hsu

机构：Tamkang University, National Taiwan University, National Taiwan University Hospital · ORCID：0000-0002-1122-0055

发表论文 22 篇 · 总被引 119 次 · h-index 4

代表论文

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study (2025 · The Lancet Oncology · 被引 67)
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial (2025 · The Lancet Oncology · 被引 13)
Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial (2025 · British Journal of Cancer · 被引 9)
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial (2025 · The Lancet Oncology · 被引 6)
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors (2025 · Investigational New Drugs · 被引 4)
Exploring novel immunotherapy in advanced esophageal squamous cell carcinoma: Is targeting TIGIT an answer? (2025 · Esophagus · 被引 4)